NOVELTY - Preparation of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f) azepines or (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepines and/or their derivatives, involves reacting respective racemic 10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepines or its derivative with N-substituted amino acid or its derivative, as resolving agent.    USE - For preparation of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f) azepines or (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepines; and for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia, cerebral spasticity, affective brain disorder or nervous function alteration in degenerative and post-ischemic disease or bipolar disorder (claimed).    ADVANTAGE - The process provide high yields of optically pure (S)-(+)- and (R)-(-)-10-hydroxy-dihydrodibenz(b,f)azepines or its derivatives; is environmentally friendly, industrically feasible and economic; avoids expensive use of menthoxyacetic acid; and does not involve the use of any transition metal (e.g. ruthenium or rhodium catalyst).    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:    (1) new intermediates of formula (IV) and (V) (N.B.: Structures (IV) and (V) are not present in the patent specification);    (2) preparing the compounds (IV) and (V), involving: reacting racemic ((S)-(+)-/(R)-(-))-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepines or its derivatives (III) with N-substituted amino acid (2) or their derivatives (IIa) to give a diastereoisomeric mixture of N-substituted amino acid derivatives of (S)-(+)- or (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepines (IV) and (V);    (3) new crystalline polymorphic form J of N-boc-protected phenylalanine ester of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxyamide;    (4) preparation of the Form J of N-boc-protected phenylalanine ester of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxyamide involving: (a) dissolving N-boc-protected phenylalanine ester of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxyamide in at least one solvent; and (b) recovering the Form J of N-boc-protected phenylalanine ester of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxyamide;    (5) new crystalline polymorphic form J of isobutyloxycarbonyl protected phenylalanine ester of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxyamide;    (6) preparation of the Form J of isobutyloxycarbonyl protected phenylalanine ester of (S)-(+)-10,ll-dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxyamide involving: (a) dissolving isobutyloxycarbonyl protected phenylalanine ester of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxyamide in at least one solvent; and (b) recovering the Form J of isobutyloxycarbonyl protected phenylalanine ester of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz(b,fJazepine-5-carboxyamide; and    (7) a pharmaceutical composition comprising therapeutic amount of eslicarbazepine or eslicarbazepine acetate, prepared by the process, and at least one carrier, excipient or diluent.